Interferon alfacon-1

Summary

Interferon alfacon-1, also called consensus interferon or CIFN, is a synthetic type‑I interferon engineered from the most common amino‑acid residues of natural IFN‑α subtypes. It has been investigated primarily as an antiviral agent for chronic hepatitis C infection, often in combination with ribavirin, and has also been mentioned in historical reports of SARS‑CoV therapy. The drug was marketed as a prescription product but has since been withdrawn from the market.

Mechanism of Action

Interferon alfacon-1 binds with high affinity to the shared type‑I interferon receptor (IFNAR1/IFNAR2) on target cells, activating the JAK‑STAT signaling cascade. This leads to transcription of interferon‑stimulated genes that exert antiviral, antiproliferative and natural‑killer‑cell‑enhancing effects. Compared with native IFN‑α, the consensus molecule shows greater potency in inducing these pathways, resulting in enhanced inhibition of viral replication and modulation of immune responses.

What the Research Shows

Randomised controlled trials in chronic hepatitis C have shown that interferon alfacon-1, given subcutaneously three times weekly, yields virological response rates comparable to or modestly superior to standard IFN‑α2b, especially in genotype 1 patients with high baseline viral loads. In one pivotal trial of 704 patients, sustained virological response at week 48 was 12 % with alfacon‑1 versus lower rates with IFN‑α2b; another head‑to‑head study reported 57 % sustained response versus 40 % for IFN‑α2b. Retreatment of prior non‑responders or relapsers demonstrated sustained responses of 13‑58 % depending on prior status. Safety data across studies indicate flu‑like symptoms and mild‑to‑moderate adverse events, with psychiatric effects more common at higher doses. Historical, non‑randomised reports have suggested possible benefit of alfacon‑1 in SARS‑CoV infection when combined with other agents, but no controlled trials exist.

Reported Benefits

Clinical evidence indicates that interferon alfacon-1 can improve sustained virological response in chronic hepatitis C, particularly for genotype 1 infections with high viral loads, where response rates were statistically higher than with IFN‑α2b. The drug also shows activity in retreatment of previous non‑responders and relapsers, offering an alternative when standard interferon regimens have failed. Its enhanced receptor binding translates into stronger antiviral and immunomodulatory effects, while overall tolerability is similar to other interferons.

Limitations of the Evidence

Interferon alfacon-1 has been withdrawn from commercial availability, limiting current clinical use. Sustained response rates, although improved in certain subgroups, remain modest in absolute terms. Evidence is confined to hepatitis C; data for other viral infections, such as SARS‑CoV, are anecdotal and lack randomised validation. Reported psychiatric adverse events are dose‑related, and long‑term outcomes have not been fully characterised. The therapeutic landscape has shifted toward newer direct‑acting antivirals, reducing the relevance of interferon‑based regimens.

Safety Considerations

Adverse events reported with interferon alfacon-1 are typical of type‑I interferons and include flu‑like symptoms (fever, fatigue, myalgia, arthralgia, headache), rigors, and mild hematologic changes. Psychiatric side‑effects such as depression or irritability have been observed more frequently at higher doses and were a common reason for treatment discontinuation. Overall, most events were mild to moderate and decreased over time, but careful monitoring is advised, especially in patients with pre‑existing mood disorders or autoimmune conditions.

How It Is Administered

Interferon alfacon-1 is administered by subcutaneous injection, usually three times per week. Clinical studies have employed doses ranging from 9 µg to 15 µg per injection (approximately 9–18 MIU), often combined with ribavirin for hepatitis C therapy. The formulation is supplied as a sterile solution for injection; no oral or inhaled preparations have been described.

Routes of Administration

Goals & Uses

• Chronic Hepatitis C treatmentAntiviralHigh
• Hepatitis C re-treatment (non-responders/relapsers)AntiviralModerate
• Melanoma (adjuvant)OncologyLow
• Chronic hepatitis CAntiviralModerate
• Antiproliferative / oncology (investigational)OncologyLow
• Hairy cell leukemiaOncologyLow
• Chronic hepatitis BAntiviral / HepatologyModerate
• Antiviral activity (broad)AntiviralLow

Contraindications

• Severe autoimmune diseaseImmunologicalHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Decompensated cirrhosisHepatic ImpairmentHigh
• Autoimmune hepatitisHepatic / AutoimmuneHigh
• Decompensated liver diseaseHepatic ImpairmentHigh
• Hypersensitivity to interferon alfacon-1 or E. coli-derived productsImmunologicHigh
• Severe bone marrow suppressionHematologicHigh
• Severe psychiatric disorders (untreated)PsychiatricHigh

Adverse Effects

• Flu-like symptoms (fever, chills, myalgia, headache)SystemicCommon
• Injection site reactionsLocalCommon
• ThrombocytopeniaHematologicCommonLow platelet count
• Thyroid dysfunction (hypothyroidism or hyperthyroidism)EndocrineUncommon
• NeutropeniaHematologicUncommonLow neutrophil count
• Depression / Mood changesPsychiatricCommon
• Depression and suicidal ideationPsychiatricCommon
• Neutropenia / leukopeniaHematologicCommon
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
• Flu‑like syndrome (fever, myalgia)SystemicCommon

Drug Interactions

• AzathioprineHigh
• Immunosuppressive agents (e.g., cyclosporine, tacrolimus)Moderate
• RibavirinModerate
• CorticosteroidsModerate
• Theophylline / CYP1A2 substratesModerate
• Myelosuppressive agents (e.g., azathioprine, hydroxyurea)High

Population Constraints

• Pediatric patients (<18 years)AgeRelative
• Patients with active substance use disorderBehavioralRelative
• Pediatric patients (<12 y)AgeRelative
• Patients with cardiac diseaseCardiovascularRelative
• Patients with renal impairmentOrgan ImpairmentRelative
• Elderly patients (>65 years)AgeRelative
• Elderly (>65 y)AgeRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization in European Union.
• United StatesInvestigationalNot FDA‑approved; used only in clinical trials.
• United KingdomUnapprovedNot licensed; available only under research protocols.

FDA approved in 1997 (NDA 020528) for chronic HCV infection. Voluntarily withdrawn from the US market by AstraZeneca in 2013. Not currently approved or actively marketed in major jurisdictions.

Evidence & Sources

• Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C
  Journal ArticleModerateSjogren MH, et al.2005-01-01T00:00:00.000000Z
• Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C
  Journal ArticleModerateMelian EB, Plosker GL2001-01-01T00:00:00.000000Z
• [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile]
  Journal ArticleModerateYasuda S, Miyata K2002-01-01T00:00:00.000000Z
• The management of coronavirus infections with particular reference to SARS
  Journal ArticleModerateWong SS, Yuen KY2008-01-01T00:00:00.000000Z
• Advances in gastrointestinal pharmacotherapy
  Journal ArticleModerateMetz DC, et al.2005-01-01T00:00:00.000000Z

Frequently Asked Questions